GE Vernova Inc. (NYSE:GEV) is one of the best IPO stocks to buy right now. On February 4, Baird analyst Ben Kallo upgraded GE Vernova to Outperform from Neutral and significantly raised the price target to $923 from $701. The firm asserted that the current energy infrastructure cycle is in its early stages, which positions GE Vernova as a primary beneficiary. Based on recent channel checks, Kallo suggested that previous concerns regarding overcapacity are unlikely to manifest in the near or intermediate ...

Chart created using Benzinga ProThe Golden Cross SignalTechnically, STM stock has shifted from repair to breakout mode. The 50-day simple moving average (SMA) at $27.18 has crossed over the 200-day SMA at 26.96, indicating strong bullish momentum taking over the chart. Momentum is turning up, volatility is compressing, and buyers have begun to show up on pullbacks rather than panicking into them. For chart purists, this is the kind of crossover that attracts systematic and momentum funds if price action con ...

PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE OF THE ANIMAL HEALTH FRANCHISE Paris, February 9, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors. Masivet® is a targeted therapy th ...

Law Offices of Frank R. Cruz Encourages Paysafe Limited (PSFE) Shareholders To Inquire About Securities Fraud Class Action Share LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Paysafe Limited ("Paysafe†or the "Company†) (NYSE: PSFE) securities between March 4, 2025 and November 12, 2025, inclusive (the "Class Period†). Paysafe investors have until April 7, 2026 to file a lea ...

U.K. banking giant NatWest is acquiring wealth manager Evelyn Partners for 2.7 billion pounds (approximately $3.6 billion).By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.Purchasing Evelyn Partners from private equ ...

Core Viewpoint - Centuri Holdings Inc. (NYSE:CTRI) is highlighted as a strong IPO stock to consider for investment, supported by a robust investment cycle in the Engineering & Construction sector [1][3]. Group 1: Investment Ratings and Price Targets - Cantor Fitzgerald initiated coverage on Centuri with an Overweight rating and a price target of $34, citing a strong multi-year investment cycle in the sector [1]. - Wells Fargo analyst Joseph O'Dea raised the price target for Centuri from $25 to $30, maintaining an Overweight rating, while noting a cautious approach in setting market expectations for 2026 [3]. Group 2: Growth Drivers - The growth of Centuri is driven by factors such as grid modernization, electrification, energy transition efforts, and increased power demand from data centers and reshoring, which contribute to record backlogs and long-term revenue visibility [2]. - Cantor Fitzgerald emphasized Centuri's highly recurring, MSA-driven utility revenue and accelerating electric growth, along with rapid post-spin deleveraging that supports significant valuation upside [2]. Group 3: Company Overview - Centuri Holdings Inc. operates as a utility infrastructure services company in North America, with four segments: US Gas Utility Services, Canadian Gas Utility Services, Union Electric Utility Services, and Non-Union Electric Utility Services [4].

Core Viewpoint - BrightSpring Health Services Inc. (NASDAQ:BTSG) is identified as a strong IPO stock with positive analyst ratings and price target increases, reflecting confidence in its operational performance and growth potential [1][2][3]. Analyst Ratings and Price Targets - BTIG analyst David Larsen raised the price target for BrightSpring Health to $55 from $50, maintaining a Buy rating, highlighting the company's consistent performance across market cycles [1]. - TD Cowen analyst Charles Rhyee increased the price target to $46 from $42, also with a Buy rating, noting the company's expected momentum due to strong trends in specialty generics [2]. - BMO Capital raised its price target to $46 from $40 with an Outperform rating, emphasizing strong pharmaceutical relationships and competitive positioning in the specialty business [3]. Company Overview - BrightSpring Health Services operates as a home and community-based healthcare services platform in the US, divided into two segments: Pharmacy Solutions and Provider Services [4].

Super Bowl LX ended in defeat for the New England Patriots as the Seattle Seahawks dominated the game with a final score of 29-13.Seahawks placekicker Jason Myers kicked a record-setting five field goals, cementing an early lead that the Seahawks never relinquished. Grammy winner Bad Bunny also became the first Latino and Spanish‑speaking solo artist to headline the Super Bowl halftime show in a performance featuring surprise appearances by Lady Gaga and Ricky Martin.Sports photographers like Julio Corte ...

Law Offices of Frank R. Cruz Encourages Richtech Robotics Inc. (RR) Shareholders To Inquire About Securities Fraud Class ActionFeb 9, 2026 12:04 PM Eastern Standard Time# Law Offices of Frank R. Cruz Encourages Richtech Robotics Inc. (RR) Shareholders To Inquire About Securities Fraud Class ActionShare--- LOS ANGELES--([BUSINESS WIRE])-- [The Law Offices of Frank R. Cruz] announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Richtech Robotics Inc. ...

A box of Wegovy pills arranged at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026.The Food and Drug Administration said Novo Nordisk's TV advertisement for its newly launched Wegovy pill for obesity included "false or misleading" claims about the medicine's abilities and benefits to patients.In a letter to Novo dated Feb. 5, the FDA said the ad misbrands the oral drug, making its distribution a violation of federal law. The agency requested that the drugmaker take immediate action to address the v ...